Q-omics provides the consensus-scored MIR193A profile across patient tissues and cancer cell-line models. MIR193A expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR193A is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, MIR193A RNA expression shows 8,291 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, THCA, and PDAC as cancer lineages where MIR193A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR193A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR193A survival associations across molecular data types. MIR193A RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR193A RNA expression–survival associations across cancer types. High MIR193A expression shows unfavorable associations in ACC, PCPG, LUSC, BLCA, THCA and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR193A RNA expression.
This table summarizes MIR193A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR193A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR193A shows lower tumor expression in THCA, KICH, BRCA and KIRC and higher tumor expression in CHOL and HNSC. The THCA box plot shows higher MIR193A RNA expression in normal versus tumor tissue (log2 FC = −0.572, t-test p < 0.001).
This table shows molecular features associated with MIR193A in patient tissues and cancer cell lines. In patient samples, MIR193A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
